by Laine Bodnar | Apr 15, 2026
Science communication sits at the intersection of research, society and decision-making. However, in recent years, the space has become more crowded with artificial intelligence (AI)-generated content, influencer commentaries and monetized narratives, which are...
by Stacey Johnson | Mar 30, 2026
Although it’s wrapping up, March is National Engineering Month in Canada. This is a great time to ask: Who is building the future of engineering in Canada, and who is still waiting for a seat at the table? Increasingly, that future doesn’t just look like roads and...
by Laya Kiani | Feb 12, 2026
In 2025, cell and gene therapy (CGT) showed growing clinical familiarity even as access and reimbursement challenges persisted. Providers and payers increasingly trusted and valued CGTs, supporting the continued expansion of late-stage programs. However, startup...
by Cal Strode | Jan 28, 2026
This year marks the fourth consecutive time I’ve covered the Alliance for Regenerative Medicine’s (ARM) State of the Industry briefing for Signals, and I’ve enjoyed tracking how the cell and gene therapy sector has evolved in real time. In 2023 and 2024, the briefings...
by Stacey Johnson | Jan 9, 2026
It’s that time of year when we look back at what was popular on Signals over the past 12 months, according to views. I am always curious to see what you are reading and perhaps you are as well? As we head into our 14th year of publishing Signals, I’m very aware of all...
by Stacey Johnson | Dec 19, 2025
A recent publication on the marketing of stem cell supplements, in the International Society for Stem Cell Research’s (ISSCR) Stem Cell Reports, sparked my curiosity about these products. While I haven’t been able to find a reliable source indicating how long stem...
Comments